Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06132035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 7, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 2024 to May 2025
    • Study sites: 4 to 7
    • Study completion date: Nov 2024 to Aug 2025
    • Start date changed from estimate of Nov 2023 to Dec 22, 2023
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration
Trial Details
NCT Number NCT06132035
Lead Sponsor Caregen Co. Ltd.
Collaborators: CBCC Global Research
Conditions
(from sponsor)		 Age-related Wet Macular Degeneration
Related terms Macular Degeneration
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov